Corneal Cross-Linking (CXL) is a specialized eye treatment used to strengthen a weakened or structurally unstable cornea. It is commonly recommended for people with keratoconus or certain forms of corneal ectasia where the cornea gradually becomes thinner and changes shape.
During CXL, specially formulated riboflavin (vitamin B2) eye drops are applied to the cornea, followed by controlled exposure to ultraviolet-A (UV-A) light. This process promotes additional bonds within the corneal tissue, helping improve its structural strength.
Who May Benefit From CXL?
An eye specialist may recommend corneal cross-linking for keratoconus when examinations show evidence of progression or increasing corneal instability. Early evaluation can help determine whether CXL is appropriate and whether other treatments, such as glasses or contact lenses, are also needed.
What Are the Benefits?
The primary goal of CXL treatment is to help slow or stop the progression of corneal weakening. Depending on the individual case, potential benefits may include:
- Strengthening the corneal structure
- Helping stabilize progressive keratoconus
- Reducing the risk of further corneal shape changes
- Supporting long-term preservation of useful vision
- Potentially reducing the need for more invasive corneal procedures in suitable patients
Recovery After CXL
Some patients experience temporary discomfort, watering, light sensitivity, or blurred vision during the initial recovery period. Healing time varies depending on the technique used and individual factors. Regular follow-up with an ophthalmologist is important to monitor corneal healing and stability.